Association Between Serum Levels of the Soluble Receptor (sRAGE) for Advanced Glycation Endproducts (AGEs) and their Receptor (RAGE) in Peripheral Blood Mononuclear Cells of Children with Type 1 Diabetes Mellitus
- 1 January 2009
- journal article
- research article
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 22 (10) , 895-904
Abstract
The binding of AGEs to RAGE is involved in diabetic vascular complications. We studied sRAGE levels and RAGE protein expression (P) together with N-carboxymethyl lysine (CML), a major AGE, in 74 patients with type 1 diabetes mellitus (DM1) and 43 healthy (C) children. sRAGE and CML levels were determined by ELISA and RAGE P was evaluated in mononuclear cells by Western immunoblotting. Serum sRAGE was higher in DM1 than in C (1430 +/- 759 vs 1158 +/- 595 pg/ml, p = 0.047), inversely correlated to diabetes duration (r = -0.265, p = 0.037) and directly correlated to LDL-cholesterol levels (r = 0.224, p = 0.039). Diabetes duration correlated independently with sRAGE (p = 0.034). Circulating CML levels were not significantly different between DM1 and C groups (3.51 +/- 1.49 vs 3.59 +/- 1.83 ng/ml, p > 0.05) and RAGE P was lower in DM1 than in C (61 +/- 46 vs 102 +/- 63%, p = 0.0001). Increased serum sRAGE in children with DM1 may provide temporary protection against cell damage and may be sufficient to eliminate excessive circulating CML.Keywords
This publication has 21 references indexed in Scilit:
- A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane‐bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)The FASEB Journal, 2008
- Calcium-regulated intramembrane proteolysis of the RAGE receptorBiochemical and Biophysical Research Communications, 2008
- Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patientsDiabetes & Vascular Disease Research, 2008
- Increased Serum Concentrations of Soluble Receptor for Advanced Glycation Endproducts in Patients with Type 1 DiabetesClinical Chemistry, 2005
- Soluble Levels of Receptor for Advanced Glycation Endproducts (sRAGE) and Coronary Artery DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Clinical implications of N ε ‐(carboxymethyl)lysine, advanced glycation end product, in children and adolescents with type 1 diabetesDiabetes, Obesity and Metabolism, 2005
- Purification and Characterization of Mouse Soluble Receptor for Advanced Glycation End Products (sRAGE)Journal of Biological Chemistry, 2004
- Impact of Metabolic Control and Serum Lipids on the Concentration of Advanced Glycation End Products in the Serum of Children and Adolescents With Type 1 Diabetes, as Determined by Fluorescence Spectroscopy and Nε-(Carboxymethyl)Lysine ELISADiabetes Care, 2003
- Biochemistry and molecular cell biology of diabetic complicationsNature, 2001
- N.epsilon.-(Carboxymethyl)lysine Is a Dominant Advanced Glycation End Product (AGE) Antigen in Tissue ProteinsBiochemistry, 1995